Pardoprunox

Drug Profile

Pardoprunox

Alternative Names: SLV-308; SME-308

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Solvay
  • Class Antidepressants; Antiparkinsonians; Anxiolytics; Benzoxazoles; Piperazines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Drug-induced dyskinesia; Parkinson's disease

Most Recent Events

  • 16 Feb 2010 Solvay Pharmaceuticals has been acquired and merged into Abbott
  • 11 Jun 2009 Pharmacodynamics data from animal studies in Parkinson's disease presented at the 13th International Congress of Parkinson's Disease and Movement Disorders (PDMD-2009)
  • 19 Apr 2008 Efficacy and safety data from a phase II trial in Parkinson's disease presented at the 60th Annual Meeting of the American Academy of Neurology (AAN-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top